Parvus Therapeutics has just scored a discovery deal with Genentech on autoimmune diseases, putting them in alliance with one of the most sought-after partners in the business.
We don’t know what the upfront is — and typically Genentech isn’t known for splurging big on discovery bets — but the whole deal, biobucks included, weighs in at a prospective $800 million.
Whatever they’re anteing up, Genentech will now hop on the Burlingame, CA-based biotech’s Navacim platform, which converts effector cells into regulatory T cells, Tregs, that in turn whip up immune regulator cells to mob the inflammatory cells that trigger autoimmune diseases like rheumatoid arthritis and multiple sclerosis.
The aim here is to restore the immune system balance and eradicate the cause of these diseases, which afflict millions. And Parvus is quite proud of its animal data to date. Now they’ll get to take the partnered programs through Phase I, with Genentech taking over at Phase II.
Roche partnering czar James Sabry called it “potentially transformative,” offering a nice endorsement of their new colleagues.
Curtis Ruegg, CEO of Parvus, noted: “Partnering with Genentech will enable Parvus to expand the Navacim pipeline to address several debilitating autoimmune diseases in gastroenterology.”
Image: Paul Sakuma AP
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 51,200+ biopharma pros who read Endpoints News by email every day.Free Subscription